Can Fite Biopharma Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
CANF•Phase 2 study protocol submitted
Can Fite Biopharma Ltd said it has submitted a Phase 2 study protocol for piclidenoson in Lowe syndrome.
Aug. 3 (Reuters) - Can Fite Biopharma Ltd CANF.TA:
- CAN FITE BIOPHARMA - CAN-FITE SUBMITS PHASE 2 STUDY PROTOCOL FOR PICLIDENOSON IN LOWE SYNDROME
